Authorized purpose: Assist analysis of user-selected discrete thyroid nodules larger than 1 cm on ultrasound when a biopsy recommendation is required, after the physician's initial image review.
Clinical role
Post-acquisition, clinician-reviewed CADe analysis with ROI contouring, quantification, visualization, and report generation after initial physician review
Images and patients
Ultrasound · Thyroid; discrete thyroid nodules
Key limitation
Keep in mind: Scope is limited to discrete thyroid nodules larger than 1 cm for which a biopsy recommendation is required and follows initial physician review. The packet describes an assistive tool and does not provide numeric clinical performance results.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Assist analysis of user-selected discrete thyroid nodules larger than 1 cm on ultrasound when a biopsy recommendation is required, after the physician's initial image review.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Thyroid; discrete thyroid nodules Input: Ultrasound images from FDA-cleared ultrasound systems; user-selected discrete thyroid nodules larger than 1 cm. The FDA comparison matrix lists DICOM 3.0, Bitmap, and JPEG image formats.
Who uses it?Intended users: Medical professionals/physicians
What does the software produce?Output: User-defined or AI-suggested ROI contour; annotations and quantified/visualized hyperechoic foci, echogenicity, texture, margin, orientation, and anechoic areas; a report based on user-entered and annotated findings that can be printed or saved as PDF.
What is its most important limitation?Key limitation: Scope is limited to discrete thyroid nodules larger than 1 cm for which a biopsy recommendation is required and follows initial physician review. The packet describes an assistive tool and does not provide numeric clinical performance results.
Clinical takeaway. Clinical role: Assist analysis of user-selected discrete thyroid nodules larger than 1 cm on ultrasound when a biopsy recommendation is required, after the physician's initial image review.
Evidence takeaway. Evidence from the reviewed source record: The FDA 510(k) summary reports standalone performance studies of AI-suggested contours for user-selected nodules on images from FDA-cleared ultrasound systems and states that the contours were effective. No sample size or numeric result is provided; no applicable FDA performance standard is identified.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Assist analysis of user-selected discrete thyroid nodules larger than 1 cm on ultrasound when a biopsy recommendation is required, after the physician's initial image review.
Post-acquisition, clinician-reviewed CADe analysis with ROI contouring, quantification, visualization, and report generation after initial physician review
Ultrasound images from FDA-cleared ultrasound systems; user-selected discrete thyroid nodules larger than 1 cm. The FDA comparison matrix lists DICOM 3.0, Bitmap, and JPEG image formats.
User-defined or AI-suggested ROI contour; annotations and quantified/visualized hyperechoic foci, echogenicity, texture, margin, orientation, and anechoic areas; a report based on user-entered and annotated findings that can be printed or saved as PDF.
Scope is limited to discrete thyroid nodules larger than 1 cm for which a biopsy recommendation is required and follows initial physician review. The packet describes an assistive tool and does not provide numeric clinical performance results.
The FDA 510(k) summary reports standalone performance studies of AI-suggested contours for user-selected nodules on images from FDA-cleared ultrasound systems and states that the contours were effective. No sample size or numeric result is provided; no applicable FDA performance standard is identified.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The FDA 510(k) summary reports standalone performance studies of AI-suggested contours for user-selected nodules on images from FDA-cleared ultrasound systems and states that the contours were effective. No sample size or numeric result is provided; no applicable FDA performance standard is identified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
AmCAD-UT regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K203555
IndependenceIndependence not established
K203555
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K203555. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Ultrasound images from FDA-cleared ultrasound systems; user-selected discrete thyroid nodules larger than 1 cm. The FDA comparison matrix lists DICOM 3.0, Bitmap, and JPEG image formats.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Windows-based standalone PC or review station with local report storage, PDF output, or printing. FDA materials identify DICOM 3.0, Bitmap, and JPEG inputs but do not establish PACS, RIS, EHR, or cloud integration.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes AmCAD-UT as a Windows-based software application, with generated reports viewed, printed, or saved as PDF files on the standalone PC or review station. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "AmCAD-UT is a Windows-based computer-assisted detection (CADe) software application device designed to assist medical professionals in analyzing thyroid ultrasound images" … "An output of the report may be viewed and sent to paper printers or saved on the standalone PC or review station as PDF file.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: User-defined or AI-suggested ROI contour; annotations and quantified/visualized hyperechoic foci, echogenicity, texture, margin, orientation, and anechoic areas; a report based on user-entered and annotated findings that can be printed or saved as PDF.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: User-defined or AI-suggested ROI contour; annotations and quantified/visualized hyperechoic foci, echogenicity, texture, margin, orientation, and anechoic areas; a report based on user-entered and annotated findings that can be printed or saved as PDF.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes AmCAD-UT as a Windows-based software application, with generated reports viewed, printed, or saved as PDF files on the standalone PC or review station. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "AmCAD-UT is a Windows-based computer-assisted detection (CADe) software application device designed to assist medical professionals in analyzing thyroid ultrasound images" … "An output of the report may be viewed and sent to paper printers or saved on the standalone PC or review station as PDF file.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Windows-based standalone PC or review station with local report storage, PDF output, or printing. FDA materials identify DICOM 3.0, Bitmap, and JPEG inputs but do not establish PACS, RIS, EHR, or cloud integration.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
22Fields reviewed
9Source classes checked
11Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 11 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 11 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K203555 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Alturion Series diagnostic ultrasound systems acquire and display ultrasound images and fluid-flow information for the labeled fetal, abdominal, cardiac, cephalic, obstetric, musculoskeletal, ophthalmic, urologic, vascular, small-organ, and lung examinations.
Modality
Ultrasound
Anatomy
Fetus; abdomen; pelvis; small organs; head; heart; peripheral vessels; musculoskeletal anatomy; ophthalmic; urologic organs; and lung
Authorized purpose: Supervised automatic ultrasound image acquisition of hand and wrist joints in adults being investigated or monitored for musculoskeletal disease.
Authorized purpose: WatchMate Software v1.2.0 processes transesophageal echocardiography data to reconstruct the left atrial appendage and assist preprocedural planning and device sizing during left-atrial-appendage closure.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.